- Opinion
- [Reporter’s View] Be aware, be prepared
- by Eo, Yun-Ho Sep 3, 2025 06:10am
- Even if it seems premature, there is nothing wrong with being prepared. Following the Trump administration’s executive order on the Most-Favored-Nation (MFN) drug pricing policy, the deadline for major multinational pharmaceutical CEOs to submit their proposed drug price reduction plans is fast approaching&8212;September 29. The MFN drug
- Policy
- Luxturna shows signif improvement in 3 out of 6 patients
- by Lee, Tak-Sun Sep 3, 2025 06:09am
- Luxturna (voretigene neparvovec, Novartis), a one-shot gene therapy that costs approximately KRW 300 million, showed clinically significant changes set by reimbursement criteria in only half of the patients. As indicated in the performance evaluation results disclosed last year, the effectiveness was only 50%. The Health Insurance Revie
- Policy
- Bill to mandate generic substitutions gains momentum
- by Lee, Jeong-Hwan Sep 3, 2025 06:09am
- On September 2, the ruling party introduced a bill to mandate generic (ingredient-based) prescriptions for medicines with unstable supply. The bill establishes the legal basis for “shortage drugs” and allows prescribing by ingredient name instead of brand name. The bill holds significance in that it amends the Pharmaceutical Affairs Ac
- Company
- Moderna’s latest variant-targeted COVID-19 vaccine approved
- by Whang, byung-woo Sep 3, 2025 06:08am
- Moderna Korea announced on the 1st that its LP.8.1 variant-targeted COVID-19 vaccine, ‘Spikevax LP Inj’, has been approved by the Ministry of Food and Drug Safety (MFDS). Spikevax LP has been confirmed to induce broad cross-immune responses against currently circulating variants, including the LP.8.1 strain, and it is authorized for use in
- Company
- 'Prevenar 20' now available at general hospitals
- by Eo, Yun-Ho Sep 2, 2025 06:11am
- The pneumococcal conjugate vaccine 'Prevenar 20,' which will soon be included in the National Immunization Program (NIP), is becoming available for prescription at general hospitals. According to industry sources, Pfizer Korea's Prevenar 20 has passed the drug committees (DC) of tertiary general hospitals, including Samsung Medical Cente
- Policy
- Kanarb and Faslodex to keep their price until ruling
- by Lee, Tak-Sun Sep 2, 2025 06:11am
- The drug prices for Boryung's hypertension treatment ‘Kanarb’ and AstraZeneca's anticancer drug ‘Faslodex,’ which were determined to be reduced by the MOHW due to the entry of generics, will be maintained at their previous levels for now. The court has decided to suspend the execution of the price reduction until the first-instance ru
- Company
- Patent suits active to release Rinvoq generics
- by Kim, Jin-Gu Sep 2, 2025 06:10am
- The race to launch generics of AbbVie’s Rinvoq (upadacitinib), an oral treatment for autoimmune diseases, is showing signs of intensifying patent disputes. With the JAK inhibitor market expanding rapidly and Rinvoq solidifying its dominance, multiple companies are expected to mount patent challenges. According to industry sources on the
- Company
- China's presence rises amid early-stage ADC candidate deals
- by Son, Hyung Min Sep 2, 2025 06:10am
- With competition in the antibody-drug conjugate (ADC) market intensifying, global deal trends are undergoing a clear shift. Transactions are now more active in the preclinical and early clinical stages, rather than in late-stage candidates, with collaborations between global pharma and Chinese companies standing out. Since the success of Enhertu
- Policy
- "MFDS' data-based drug shortage response"
- by Lee, Jeong-Hwan Sep 2, 2025 06:09am
- The Ministry of Health and Welfare (MOHW) announced that it will address drug shortages by utilizing information from the "Pharmaceutical Production, Supply, and Prescription Data-based Supply Risk Prediction System," which is currently being established by the Ministry of Food and Drug Safety (MFDS). The MOHW has also proposed drug short
- Company
- How will fate fare for Roche’s two anticancer drugs?
- by Eo, Yun-Ho Sep 1, 2025 06:05am
- The industry’s eyes are on whether Roche's two anti-cancer drugs, which have faced repeated failures, will succeed in securing reimbursement listing this time. According to industry sources, Roche Korea's treatment for refractory diffuse large B-cell lymphoma(DLBCL), ‘Polivy (polatuzumab vedotin)’ and the PD-L1 inhibitor-based immunoth
